Jiangsu Zhongbang Pharmaceutical Co. Ltd. has been founded in 2001. It is a wholly-owned subsidiary of Red Sun Group which is one of Chinese top 500 manufacturers. As a high-tech enterprise, Zhongbang focuses on developing and producing pharmaceutical intermediates, APIs and finished products. The registered capital of Jiangsu Zhongbang is $2.6 million and total area is 400,000m2. After a rapid growth in its business during recent years, Jiangsu Zhongbang has 4 subsidiary companies and more than 700 employees.

Jiangsu Zhongbang concentrates on the production technique of proton pump inhibitors “Prazole”, anti-hypertension “Sartan” and anti-coagulants “Xaban” for more than 15 years. And now Jiangsu Zhongbang owns the complete industry chain from intermediate to API and finished products.

Jiangsu Zhongbang is committed to “Quality” as a way of life regardless of commercial consequences. Thanks to the integrated and stringent system of quality control and quality assurance, the Company has been the leader of cGMP implementation in China. Its non-sterile APIs have been approved by MFDS of Korea, and other national regulatory authorities. Telmisartan and Esomeprazole Magnesium Trihydrate have obtained CEP certificates, and Japanese MF registration.

Jiangsu Zhongbang aims to make social responsibility a part of our day to day business activities by providing a continuous flow of innovative new medicines domestically and internationally.